(Invited) Theranostics with Lanthanide Doped Nanoparticles

In recent years, a significant amount of research has focused on nanoparticle-based “theranostic” agents for the treatment of a wide array of diseases, including cancer. This new paradigm in personalized medicine intends to exploit nanoplatforms that carry both therapeutic and diagnostic (theranostic) modalities. Compared with delivering drugs or imaging agents separately, theranostic agents can simultaneously deliver them to specific sites, enabling detection and treatment of disease in a single procedure. Many theranostic nanoplatforms are triggered by light, however, the vast majority of these are limited in that the ultraviolet or visible excitation light used has minimal applicability in biological applications. Lanthanide doped nanoparticles, on the other can be excited with biologically friendly near-infrared light (in the biological windows) and can emit in the ultraviolet, visible or near-infrared regions through a multiphoton upconversion process while simultaneously emitting in the near-infrared region through a Stokes or downshifted process. Hence, the upconversion luminescence can be used to trigger the therapeutic application (drug delivery, photodynamic therapy, etc.) while the near-infrared luminescence can be used for the diagnostic modality (bioimaging, nanothermometry, etc). In this presentation, we will introduce lanthanide doped nanoparticles and demonstrate their usefulness in theranostics. In particular, we will show complex nanoparticle architectures can endow further functionality to these nanoparticles including the ability to decouple the theranostic processes that are conventionally delivered simultaneously.